These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12065572)

  • 1. Comment on "Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols".
    Ferrari S; Mercuri M; Bacci G
    J Clin Oncol; 2002 Jun; 20(12):2910; author reply 2910-1. PubMed ID: 12065572
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience.
    Bacci G; Balladelli A; Palmerini E; Alberghini M; Pollastri P; Galletti S; Mercuri M; Picci P
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):908-12. PubMed ID: 19131777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor size and prognosis in aggressively treated osteosarcoma.
    Bieling P; Rehan N; Winkler P; Helmke K; Maas R; Fuchs N; Bielack S; Heise U; Jurgens H; Treuner J; Romanowski R; Exner U; Kotz R; Winkler K
    J Clin Oncol; 1996 Mar; 14(3):848-58. PubMed ID: 8622033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
    Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
    Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma.
    Song WS; Jeon DG; Kong CB; Cho WH; Koh JS; Lee JA; Yoo JY; Jung ST; Shin DS; Lee SY
    Ann Surg Oncol; 2011 Jun; 18(6):1710-6. PubMed ID: 21222166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
    Serra M; Scotlandi K; Reverter-Branchat G; Ferrari S; Manara MC; Benini S; Incaprera M; Bertoni F; Mercuri M; Briccoli A; Bacci G; Picci P
    J Clin Oncol; 2003 Feb; 21(3):536-42. PubMed ID: 12560446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
    Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
    J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
    Rehan N; Bieling P; Winkler P; Helmke K; Maas R; Baldini N; Heise U; Fuchs N; Winkler K
    Klin Padiatr; 1993; 205(4):200-9. PubMed ID: 8377444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
    Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
    J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic osteosarcoma: a curable advanced malignancy.
    Brockstein BE
    J Clin Oncol; 2004 Dec; 22(24):5017; author reply 5017-8. PubMed ID: 15611520
    [No Abstract]   [Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: is a good response to preoperative treatment an indication to reduce postoperative chemotherapy?
    Bacci G; Picci P; Gherlinzoni F; Van Horn JR; Orlandi M; Normand AR; Manfrini M; Pignatti G; Campanacci M
    Chemioterapia; 1986 Apr; 5(2):140-3. PubMed ID: 3458546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of increased angiogenesis in osteosarcoma.
    Kreuter M; Bieker R; Bielack SS; Auras T; Buerger H; Gosheger G; Jurgens H; Berdel WE; Mesters RM
    Clin Cancer Res; 2004 Dec; 10(24):8531-7. PubMed ID: 15623635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
    Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
    Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results.
    Bacci G; Avella M; Brach Del Prevert A; Capanna R; Fiorentini G; Malaguti C; Picci P; Rosito P; Campanacci M
    Chemioterapia; 1988 Apr; 7(2):138-42. PubMed ID: 3165058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
    Kempf-Bielack B; Bielack SS; Jürgens H; Branscheid D; Berdel WE; Exner GU; Göbel U; Helmke K; Jundt G; Kabisch H; Kevric M; Klingebiel T; Kotz R; Maas R; Schwarz R; Semik M; Treuner J; Zoubek A; Winkler K
    J Clin Oncol; 2005 Jan; 23(3):559-68. PubMed ID: 15659502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.